Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

clear all | select all

Conference Years:

clear all | select all

Days Within Meeting:

clear all | select all

Conferences:

Availability:

clear all | select all

Participation Type:

clear all | select all

Topic Tracks*:

clear all | select all

Organ Site Tracks*:

Showing session: reset

New Drugs on the Horizon 1

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 6 of 6
New Drugs on the Horizon 1
  •  
  • Free
  • Unknown permission
    for presentation
  •  
  •  
Co-Chairperson
Indrawan J. Mcalpine
Pfizer Global R&D, San Diego, CA, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
New Drugs on the Horizon 1
Discovery and pre-clinical pharmacology of AZD0156: A first-in-class potent and selective inhibitor of Ataxia telangiectasia mutated (ATM) kinase
Elaine Cadogan
AstraZeneca, Cambridge, United Kingdom
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
New Drugs on the Horizon 1
  •  
  • Permission not
    granted for presentation
  •  
  •  
A selective CDC7 inhibitor (LY3177833) impacts chromosome dynamics and has robust and durable activity in PDX tumor models
Xiang S. Ye
Eli Lilly and Company, Shanghai, China
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
New Drugs on the Horizon 1
JNJ-61610588: A human anti-VISTA antibody induces antitumor responses via a unique mechanism of action
Linda A. Snyder
Janssen Research & Development, LLC, Spring House, PA, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
New Drugs on the Horizon 1
MBG453: A high affinity, ligand-blocking anti-TIM-3monoclonal Ab
Catherine A. Sabatos-Peyton
Novartis Institutes for BioMedical Research (NIBR), Cambridge, MA, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
New Drugs on the Horizon 1
  •  
  • Permission not
    granted for presentation
  •  
  •  
First-in-class T cell-redirecting bispecific antibody targeting glypican-3: a highly tumor-selective antigen
Takahiro Ishiguro
Chugai Pharmaceutical Co., Ltd., Japan
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 6 of 6